INFLA HARMONY™: Back & Posture

Yes, more or less. Assurance Maladie, France’s national health insurance body, writes that low back pain, or “lombalgie,” is “commonly called ‘back pain’ or ‘lumbago’,” and that it is “pain, often intense, in the lumbar vertebrae, located in the lower back.”

France’s National Authority for Health (HAS) gives a more technical definition: “Low back pain is defined as pain located between the thoraco-lumbar junction and the lower gluteal fold.”

The distinction that really matters lies elsewhere. A distinction is made between “common low back pain” and “specific low back pain,” which, according to Assurance Maladie, is “linked to underlying illnesses such as scoliosis, ankylosing spondylitis, a vertebral fracture, an infection localised to the spine, a spinal tumour.” HAS defines common low back pain as “lower back pain with no warning signs.” It is this form, by far the most frequent, that this page is about.

Sources (French institutions, quotes translated from French): Assurance Maladie, ameli.fr, “Low back pain, what are we talking about?,” updated 29 January 2026; HAS, “Management of the patient with common low back pain,” memo published 4 April 2019. Accessed 22 August 2026.

Very. Assurance Maladie gives a figure that leaves few people out: “Low back pain is common: 84% of people have had, have, or will have low back pain.” At work, it cites “2 employees out of 3” who “have had, have, or will have back problems.”

On a global scale, Inserm, the French national medical research institute, ranks the subject even higher: “In 2016, the Global Burden of Disease Study showed that among 310 chronic illnesses, common low back pain was the leading cause of years lived with disability worldwide.”

Sources (French institutions, quotes translated from French): Assurance Maladie, ameli.fr (“Low back pain, what are we talking about?”; “Back pain and working life,” updated 17 May 2022); Inserm, collective expert review “Physical activity: prevention and treatment of chronic illnesses,” summary published 11 February 2019. Accessed 22 August 2026.

It is even the leading cause cited. Assurance Maladie writes: “Very often, the cause of back pain is a sedentary lifestyle, a lack of activity. The muscles relax, and are not strong enough to do their job.”

It then defines this behaviour precisely: “A sedentary lifestyle is a waking state characterised by very low energy expenditure,” and gives examples that describe an office day: “travelling by motor vehicle; sitting to read, write, do office work, study, spend time in front of a screen.” “Prolonged sitting” is explicitly listed among the postures cited as strains.

The practical advice that goes with it is simple: “it is beneficial to limit and break up time spent sitting, in addition to regular physical activity.” The same source recommends walking for a few minutes and stretching after two hours spent sitting.

A counter-intuitive detail flagged by Assurance Maladie: this is no longer just a subject for settled adults, since “with the rise of sedentary behaviour and inactivity, it is increasingly affecting young people too.”

Sources (French agency, quotes translated from French): Assurance Maladie, ameli.fr, “Low back pain, what are we talking about?” and “Back pain: the right treatment is movement!,” updated 9 April 2025. Accessed 22 August 2026.

Not as long as people fear. France’s National Authority for Health makes this a point to communicate to the patient: “It is essential to give reassuring information about the prognosis: in 90% of cases, common low back pain resolves favourably within 4 to 6 weeks.”

Assurance Maladie describes the same timeline and names the stages: up to 4 to 6 weeks, low back pain is called “acute”; “between 4/6 weeks and 12 weeks, it is called ‘subacute'”; and “when back pain continues beyond 3 months (12 weeks), it is ‘chronic’ and specific management is needed.”

HAS also recommends “reassessing the patient 2 to 4 weeks after an acute flare-up of low back pain.”

Sources (French institutions, quotes translated from French): HAS, memo of 4 April 2019; Assurance Maladie, ameli.fr, “Back pain, how to avoid chronic pain,” updated 9 April 2025. Accessed 22 August 2026.

This is the question intuition gets wrong most often, and it is probably the most useful piece of information on this page.

Assurance Maladie titles a section “The real enemy of the back is rest,” and writes: “Bed rest for low back pain is not recommended. Rest and inactivity risk making your pain persist in the long term.”

It adds: “It is essential to resume normal activity as soon as possible, to prevent the vicious circle of chronic back pain from setting in,” and sums it up in one line: “Stop moving, and you seize up!”

A Cochrane review compared the two pieces of advice. On acute low back pain, its conclusion is measured but points the same way: “Moderate quality evidence shows that patients with acute LBP may experience small benefits in pain relief and functional improvement from advice to stay active compared to advice to rest in bed.” Modest benefits, then, but in favour of movement.

A related point, often misunderstood: according to Assurance Maladie, “there is no link between the intensity of pain and the severity of back pain.”

Sources (French agency, quotes translated from French, plus Cochrane): Assurance Maladie, ameli.fr, “Back pain: the right treatment is movement!” and “Low back pain, what are we talking about?”; Dahm KT, Brurberg KG, Jamtvedt G, Hagen KB, “Advice to rest in bed versus advice to stay active for acute low-back pain and sciatica,” Cochrane Database of Systematic Reviews 2010, CD007612. Accessed 22 August 2026.

The phrase comes from Assurance Maladie, which made it the title of its campaign. France’s National Authority for Health puts it in its own terms: “Physical exercise is the main treatment enabling a favourable course of common low back pain (grade B).” In its table of non-drug treatments, “Self-management and resuming daily activities” and “Adapted physical activity and sporting activities” are classed as “Indicated” as first-line options.

Inserm is more specific about the chronic form: “In chronic low back pain of common origin, adapted physical activity in the form of structured programmes combining specific exercises and non-specific physical activity leads to a reduction in pain and an improvement in function, both at the end of treatment and in the long term, and reduces long-term inability to work.”

The largest Cochrane review on the subject, which pooled 249 trials and 24,486 participants, is more cautious. It concludes: “We found moderate-certainty evidence that exercise is probably effective for treatment of chronic low back pain compared to no treatment, usual care or placebo for pain,” while noting that the effect observed on functional limitations “is small for functional limitations, not meeting our threshold for minimal clinically important difference.” The authors add: “There is a lot of research in this field but we need bigger and better designed studies to allow us to draw firm conclusions.”

Sources (French institutions, quotes translated from French, plus Cochrane): HAS, memo of 4 April 2019; Inserm, collective expert review 2019; Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MW, “Exercise therapy for chronic low back pain,” Cochrane Database of Systematic Reviews, 28 September 2021, CD009790.pub2; Assurance Maladie, ameli.fr. Accessed 22 August 2026.

This is the most important question on this page, and the only one whose answer admits no commercial nuance.

France’s National Authority for Health publishes a list of “red flags,” warning signs “pointing to an underlying condition requiring specific and/or urgent management.” Here it is, as it appears in the memo:

• “Non-mechanical pain: pain that gradually worsens, present at rest and particularly at night”
• “Extensive neurological symptom (deficit in bladder or anal sphincter control, motor impairment in the legs, cauda equina syndrome)”
• “Paraesthesia in the pubic area (or perineum)”
• “Significant trauma (such as a fall from height)”
• “Unexplained weight loss”
• “History of cancer, presence of a febrile syndrome”
• “Intravenous drug use, or prolonged use of corticosteroids (for example asthma therapy)”
• “Significant structural deformity of the spine”
• “Chest pain (dorsal spinal pain)”
• “Age of onset under 20 or over 55”
• “Fever”
• “Deterioration in general condition”

Two clarifications from HAS, worth keeping in mind. First, this check “should be carried out for any recent lower back pain, or worsening of symptoms, or appearance of new symptoms.” Second, “the specificity of the warning signs (see ‘red flags’) taken in isolation is limited; it is their combination that should draw attention and raise suspicion of an underlying condition.”

This list does not replace an examination: it indicates when to seek one. If any of these signs is present, the right course of action is to see a doctor, not to order a food supplement.

Source (French institution, quotes translated from French): HAS, “Management of the patient with common low back pain,” memo published 4 April 2019. Accessed 22 August 2026.

Generally not, and this often surprises people. France’s National Authority for Health is explicit: “In the absence of a red flag, there is no indication for spinal imaging in the case of an acute flare-up of low back pain (grade C),” and it is even recommended “to explain to the patient why imaging is not necessary.”

The reason lies in what would be found. Assurance Maladie explains it plainly: “the back is never perfect and is subject to ageing: these X-ray examinations could therefore give the impression that these minor age-related imperfections are the cause of the low back pain.” HAS recommends, in the same spirit, “explaining to the patient the lack of systematic correlation between symptoms and radiological signs.”

Beyond three months, the logic reverses: in the absence of a red flag, HAS then recommends spinal imaging for chronic low back pain, with MRI being the recommended examination.

Sources (French institutions, quotes translated from French): HAS, memo of 4 April 2019; Assurance Maladie, ameli.fr. Accessed 22 August 2026.

Rarely for a mechanical reason. France’s National Authority for Health recommends looking early for “yellow flags,” psychosocial factors that predict a shift to chronic pain. These include “emotional problems such as depression, anxiety, stress,” “inappropriate attitudes and beliefs about back pain, such as the idea that pain represents a danger,” and “inappropriate pain-related behaviour, particularly avoidance or reduction of activity, driven by fear.”

Assurance Maladie describes the same downward spiral in everyday language: “Back pain is often accompanied by a fear of getting hurt again. This can lead to stopping activities, or even losing the habit of moving. These pauses lead to stiffness, a lack of ligament flexibility, weakened back muscles… causing further episodes of low back pain.”

It also cites the working context: “monotonous tasks, job dissatisfaction, little recognition received in return for effort made.”

Sources (French institutions, quotes translated from French): HAS, memo of 4 April 2019; Assurance Maladie, ameli.fr. Accessed 22 August 2026.

Yes, under certain conditions. Assurance Maladie states that if the link with working activity “is established, meaning it meets the recognition criteria for occupational illness listed in the relevant tables (tables 97 and 98 of occupational illnesses under the general scheme), the occupational origin of the illness will be recognised.” And: “Requests for recognition must be sent by the insured person to their health insurance fund.”

On work itself, the same source rejects an overly simple reading: “suitable work activity helps mobilise and strengthen the back muscles,” and “working life, as well as the commute to get there, helps maintain the mobility and tone of the back muscles.” HAS recommends seeking the expertise of the occupational health doctor “in the case of repeated sick leave or leave extending beyond 4 weeks.”

Sources (French institutions, quotes translated from French): Assurance Maladie, ameli.fr (“Low back pain, what are we talking about?”; “Back pain and working life”); HAS, memo of 4 April 2019. Accessed 22 August 2026.

No. This is not a note of caution, it is the very definition of the product. ANSES, France’s food safety agency, states it as follows: “A food supplement is not a medicine, and can therefore not, by definition, claim any therapeutic effect.”

A food supplement is therefore no substitute for a diagnosis, for treatment, or for the advice of a doctor, physiotherapist or pharmacist. The Agency gives five pieces of advice that apply to any product in this category, including ours: “Seek advice from a health professional, avoid prolonged, repeated or multiple use, follow the conditions of use, be wary of products presented as miracle cures, favour products sold through the best-controlled channels.”

It also suggests starting with a question: “Before consuming a food supplement, the first question to ask is: do I really need it?”

Source (French agency, quotes translated from French): ANSES, “Food supplements: the need for informed consumption,” anses.fr. Accessed 22 August 2026.

No. The memo from France’s National Authority for Health details two tables, one for non-drug treatments, the other for drug treatments. No food supplement appears in either. What does appear: self-management and resuming daily activities, adapted physical activity, physiotherapy, education on pain neurophysiology, manual techniques, psychological interventions, multidisciplinary rehabilitation programmes, then drug treatments, injections and surgery.

HAS also rules out a supplement often mentioned in this context: “There is no indication for treatment with antibiotics (grade B), nor with vitamin D (grade B).”

We sell a food supplement, not a treatment pathway. This is precisely why this page describes a composition, not results.

Source (French institution, quote translated from French): HAS, memo of 4 April 2019. Accessed 22 August 2026.

Because its journey through the body works against it at every stage. ANSES sums it up: “The pharmacokinetic profile of curcumin shows very low oral absorption, rapid metabolism and elimination.”

The most telling figure comes from a study conducted in humans with single doses of 500 to 12,000 mg: “Curcumin is undetectable in serum for administered doses of 500 to 8,000 mg.” On elimination: “Numerous studies in rats have shown that most curcumin is found in stools after oral ingestion, while a tiny amount is found in urine.”

The Agency lists the workarounds used by manufacturers: “the addition of adjuvants such as piperine, the inclusion of curcumin in a lipophilic matrix, encapsulation with surfactants, or the administration of structural analogues.” The form used in this formula falls under the second category.

Source (French agency, quotes translated from French): ANSES, opinion on referral No. 2019-SA-0111. Accessed 22 August 2026.

A standardised, or titrated, extract is an extract whose content of a given compound is measured, stated, and kept consistent from one batch to the next.

The gap with plain plant powder is considerable. According to ANSES, curcuminoids are present in rhizomes “at concentrations that vary greatly depending on geographic origin, soil composition and growing conditions,” “generally between 0.3 and 5.4% (w/w, dry weight),” while the purification process “yields an orange-yellow crystalline powder containing more than 95% curcuminoids.”

Standardisation is not, however, an absolute guarantee. In a survey reported by ANSES, “in four samples, the curcuminoid content was lower than stated,” and “in one sample, the presence of piperine was identified even though the label made no mention of it.”

One clarification, which works against us as much as against anyone else, to finish: a standardisation tells you a content. It says nothing about absorption, and nothing about any effect. These are three separate questions.

Source (French agency, quotes translated from French): ANSES, opinion on referral No. 2019-SA-0111. Accessed 22 August 2026.

Yes, and it would be wrong to leave this out on the page of a product that contains it.

The French and Italian vigilance schemes “have recorded more than 40 cases of hepatitis occurring between 2002 and 2021 during the consumption of food supplements containing turmeric or curcumin, for which causality is considered likely or very likely in 9 cases.” ANSES “advises against the consumption of turmeric by people suffering from disorders of the biliary tract” and draws consumers’ attention “to the risks of interaction between curcumin and certain medicines such as anticoagulants, anticancer medicines and immunosuppressants.”

On amounts, the Agency considers that “taking such supplements raises no particular concern as long as consumption does not exceed an intake of 153 mg of curcumin per day for a 60 kg adult,” while immediately noting that the acceptable daily intake “does not apply to formulations” in which curcumin’s bioavailability has been increased. This formula provides 92 mg of curcuminoids per daily dose and uses an encapsulated form: one more reason not to exceed the stated dose, and to seek medical advice if you are on ongoing treatment.

The full precautions for use appear in the dedicated tab, at the top of this page.

Source (French agency, quotes translated from French): ANSES, opinion on referral No. 2019-SA-0111. Accessed 22 August 2026.

Because European Regulation 1924/2006 governs health claims, and the case of plants has never been settled.

EFSA was already documenting this in 2011: of the 4,637 claims transmitted to the Agency by the European Commission between July 2008 and March 2010, “1,548 claims on ‘botanicals’ have been placed on hold by the Commission pending further consideration on how to proceed with these.”

Fourteen years on, the situation is unchanged. The Court of Justice of the European Union confirmed this in its ruling of 30 April 2025: “as the Commission acknowledged at the hearing before the Court, the assessment of health claims relating to botanical substances has been suspended and the list concerning such claims has not yet been drawn up.”

A brand that makes a claim regardless has no information that we do not have. It is simply taking a risk that we do not take.

Sources: EFSA, statement of 28 July 2011; CJEU, ruling of 30 April 2025, case C-386/23, Novel Nutriology, paragraph 55 (EUR-Lex, CELEX 62023CJ0386). Accessed 22 August 2026.

One nuance exists, however, and we apply it. Among the claims still pending are statements relating to joint health, usable under the transitional regime provided for in Article 28 of the Regulation. On this basis, and this basis only, this page states that turmeric and boswellia contribute to joint health. No statement referring to a disease is possible, and you will find none here.

It is not recommended in cases of biliary obstruction or biliary function disorders, for pregnant or breastfeeding women, for people with diabetes, or when taking anticoagulants, anticancer medicines or immunosuppressants.

Do not exceed the recommended daily dose. This product is not a substitute for a healthy lifestyle or a varied, balanced diet. Keep out of reach of young children.

If you are on any ongoing treatment, seek the advice of a doctor or pharmacist before taking it.

Every page in this range presents the same product: the same actives, at the same amounts, in the same 120-capsule bottle, with the same dose of four capsules a day. What differs from page to page is not the formula, it is the path by which you arrived here and the context we take the time to document.

This page is written for readers whose days are spent sitting: desk, screens, commutes, few chances to get up. The other pages cover the same composition from a different angle, drawing on the same public sources, and you will find the same list of actives on each: after 50, if your movements are repetitive at work, if you want to understand what a formula contains, if you are researching pain that settles in, or the sciatica supplement page when the discomfort runs down the leg.

Whichever path you take, the full composition is published in the Ingredients tab on this page. Four options are available: single purchase at €39.90 instead of €49.90, pack of 2 at €74.90 instead of €89.90, pack of 3 at €99.90 instead of €124.90, and a monthly subscription at €29.90 instead of €39.90, cancellable at any time.

On the topic of joints, European regulation authorises one statement under the pending claims: boswellia contributes to the health of joints and bones. This formula provides 307 mg per daily dose, as a concentrated extract standardised to 65% boswellic acids, providing 200 mg of boswellic acids.

Beyond this sentence, nothing more can be stated, by us or by anyone else.

The same framework applies: turmeric contributes to joint health. This formula provides 400 mg of Longvida® curcumin, including 92 mg of curcuminoids, extracted using the patented “Solid Lipid Curcumin Particle” technology.

As ordinary curcumin is very poorly absorbed, it was the form that guided this choice, not the raw quantity. Here again, nothing else can be stated.